When will Hims & Hers report earnings and how might HIMS stock react?

Hims & Hers reports earnings after market close on 23 Feb 2026. HIMS stock could gap on guidance, prescription metrics, or margin updates. Volatility is likely; prepare for swings in excess of 10% depending on the print.

What is the Meyka AI grade for HIMS and what does it mean for HIMS stock?

Meyka AI assigns HIMS a **76.28** score (B+, BUY). The grade weighs benchmark, sector, growth, metrics, and analyst views. It is informational and not a guarantee or investment advice.

What are the key valuation metrics investors should watch for HIMS stock?

Watch **PE 30.72**, **price-to-sales 1.62**, **price-to-book 6.33**, and debt-to-equity **1.92**. Also monitor free cash flow and recurring revenue growth trends after earnings.

How reliable is the Meyka AI forecast for HIMS stock

Meyka AI's forecast model projects targets like **USD 64.90** in one year. These are statistical scenarios based on historical and alternative data. Forecasts are model-based projections and not guarantees.

US Stocks

Pre-Market: HIMS (Hims & Hers NYSE) $16.27 on 18 Feb 2026: earnings in focus

ByHuzaifa Zahoor February 18, 2026February 18, 2026

In pre-market trading on 18 Feb 2026 HIMS stock sits at USD 16.27, down slightly from yesterday, as investors position ahead of Hims & Hers Health, Inc.’s earnings due 23 Feb 2026. The company will report results after the market close, and expectations center on recurring prescription growth and margin progress. Market metrics show a PE of 30.72 and EPS of 0.53, while the stock trades well below its 50-day average of USD 31.23 and 200-day average of USD 45.48. We review fundamentals, technicals, analyst sentiment, and a Meyka forecast before the print.